Samsung Biologics Co Ltd (207940) - Net Assets
Based on the latest financial reports, Samsung Biologics Co Ltd (207940) has net assets worth ₩12.18 Trillion KRW (≈ $8.25 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩18.34 Trillion ≈ $12.43 Billion USD) and total liabilities (₩6.16 Trillion ≈ $4.17 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 207940 total assets for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩12.18 Trillion |
| % of Total Assets | 66.42% |
| Annual Growth Rate | 32.97% |
| 5-Year Change | 137.12% |
| 10-Year Change | 292.98% |
| Growth Volatility | 99.35 |
Samsung Biologics Co Ltd - Net Assets Trend (2014–2024)
This chart illustrates how Samsung Biologics Co Ltd's net assets have evolved over time, based on quarterly financial data. Check Samsung Biologics Co Ltd (207940) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Samsung Biologics Co Ltd (2014–2024)
The table below shows the annual net assets of Samsung Biologics Co Ltd from 2014 to 2024. For live valuation and market cap data, see 207940 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩10.90 Trillion ≈ $7.39 Billion |
+10.93% |
| 2023-12-31 | ₩9.83 Trillion ≈ $6.66 Billion |
+9.42% |
| 2022-12-31 | ₩8.98 Trillion ≈ $6.09 Billion |
+80.01% |
| 2021-12-31 | ₩4.99 Trillion ≈ $3.38 Billion |
+8.53% |
| 2020-12-31 | ₩4.60 Trillion ≈ $3.12 Billion |
+5.61% |
| 2019-12-31 | ₩4.35 Trillion ≈ $2.95 Billion |
+4.79% |
| 2018-12-31 | ₩4.16 Trillion ≈ $2.82 Billion |
+4.50% |
| 2017-12-31 | ₩3.98 Trillion ≈ $2.69 Billion |
-2.59% |
| 2016-12-31 | ₩4.08 Trillion ≈ $2.77 Billion |
+47.12% |
| 2015-12-31 | ₩2.77 Trillion ≈ $1.88 Billion |
+339.94% |
| 2014-12-31 | ₩630.73 Billion ≈ $427.44 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Samsung Biologics Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 540127279119000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩5.09 Trillion | 46.65% |
| Other Components | ₩5.82 Trillion | 53.35% |
| Total Equity | ₩10.90 Trillion | 100.00% |
Samsung Biologics Co Ltd Competitors by Market Cap
The table below lists competitors of Samsung Biologics Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ferrovial SE
NASDAQ:FER
|
$46.59 Billion |
|
Sun Life Financial Inc.
TO:SLF
|
$46.60 Billion |
|
China Citic Bank Corp Ltd Class A
SHG:601998
|
$46.65 Billion |
|
East Money Information Co Ltd
SHE:300059
|
$46.65 Billion |
|
Skandinaviska Enskilda Banken AB (publ)
ST:SEB-A
|
$46.56 Billion |
|
WuXi AppTec Co Ltd
SHG:603259
|
$46.48 Billion |
|
Diageo plc
MX:DEON
|
$46.39 Billion |
|
Shanghai Pudong Development Bank Co Ltd
SHG:600000
|
$46.35 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Samsung Biologics Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 9,830,492,412,340 to 10,904,676,062,010, a change of 1,074,183,649,670 (10.9%).
- Net income of 1,083,315,885,980 contributed positively to equity growth.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩1.08 Trillion | +9.93% |
| Other Changes | ₩-9.13 Billion | -0.08% |
| Total Change | ₩- | 10.93% |
Book Value vs Market Value Analysis
This analysis compares Samsung Biologics Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 9.69x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 24.71x to 9.69x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩60099.01 | ₩1485000.00 | x |
| 2018-12-31 | ₩62804.63 | ₩1485000.00 | x |
| 2019-12-31 | ₩65812.04 | ₩1485000.00 | x |
| 2020-12-31 | ₩69504.77 | ₩1485000.00 | x |
| 2021-12-31 | ₩74641.85 | ₩1485000.00 | x |
| 2022-12-31 | ₩126232.53 | ₩1485000.00 | x |
| 2023-12-31 | ₩138119.15 | ₩1485000.00 | x |
| 2024-12-31 | ₩153211.51 | ₩1485000.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Samsung Biologics Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 9.93%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 23.82%
- • Asset Turnover: 0.26x
- • Equity Multiplier: 1.59x
- Recent ROE (9.93%) is above the historical average (8.83%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -16.03% | -91.21% | 0.08x | 2.27x | ₩-155.72 Billion |
| 2015 | 69.20% | 2103.66% | 0.02x | 2.15x | ₩1.64 Trillion |
| 2016 | -4.33% | -60.02% | 0.04x | 1.85x | ₩-585.06 Billion |
| 2017 | -2.44% | -20.87% | 0.06x | 1.81x | ₩-494.62 Billion |
| 2018 | 5.39% | 41.83% | 0.09x | 1.44x | ₩-191.44 Billion |
| 2019 | 4.66% | 28.92% | 0.12x | 1.36x | ₩-232.54 Billion |
| 2020 | 5.24% | 20.69% | 0.18x | 1.40x | ₩-218.90 Billion |
| 2021 | 7.89% | 25.10% | 0.20x | 1.60x | ₩-105.52 Billion |
| 2022 | 8.88% | 26.59% | 0.18x | 1.85x | ₩-100.39 Billion |
| 2023 | 8.72% | 23.21% | 0.23x | 1.63x | ₩-125.36 Billion |
| 2024 | 9.93% | 23.82% | 0.26x | 1.59x | ₩-7.15 Billion |
Industry Comparison
This section compares Samsung Biologics Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $202,051,042,045
- Average return on equity (ROE) among peers: -14.86%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Samsung Biologics Co Ltd (207940) | ₩12.18 Trillion | -16.03% | 0.51x | $46.59 Billion |
| ORIENTBIO Inc. (002630) | $44.21 Billion | 0.00% | 0.54x | $71.52 Million |
| Green Cross (005250) | $210.22 Billion | 1.73% | 6.63x | $283.20 Million |
| Green Cross Holdings Preference Shares (005257) | $1.38 Trillion | 3.43% | 0.63x | $2.29 Million |
| Pharmicell (005690) | $63.87 Billion | 14.80% | 0.48x | $411.92 Million |
| GeneOne Life Science Inc (011000) | $40.90 Billion | -126.78% | 1.91x | $164.07 Million |
| HLB Co. Ltd (028300) | $174.68 Billion | 14.51% | 0.74x | $2.76 Billion |
| Mgenplus Co. Ltd. (032790) | $10.14 Billion | -54.19% | 2.17x | $16.13 Million |
| Daesung Microbiological Labs. Co. Ltd (036480) | $35.42 Billion | 1.69% | 0.64x | $15.71 Million |
| Seoulin Bioscience Co.Ltd (038070) | $41.57 Billion | 10.01% | 0.45x | $24.62 Million |
| Hyundai Bioscience Co. Ltd (048410) | $22.49 Billion | -13.82% | 0.46x | $384.00 Million |
About Samsung Biologics Co Ltd
Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates through Contract Development and Manufacturing Organization (CDMO), and Biopharmaceutical Development and Commercialization segments. Its development services include late discovery, cell line de… Read more